SOPHiA GENETICS and AstraZeneca Partner to Develop Two Companion Diagnostics for Precision Oncology
SOPHiA GENETICS and AstraZeneca have launched a multi-year collaboration to develop two companion diagnostics for solid tumours and blood cancers, supporting broader access to precision oncology therapies.
Companion Diagnostic Programme | 18/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy